Skip to main content
. Author manuscript; available in PMC: 2018 Oct 25.
Published in final edited form as: Biol Blood Marrow Transplant. 2016 Apr 4;22(7):1218–1226. doi: 10.1016/j.bbmt.2016.03.027

Figure 4:

Figure 4:

The estimates of relapse-free survival (A), overall survival (B), cumulative incidence of relapse (C) and non-relapse mortality (D) by post-remission therapy in 82 patients with first complete remission for at least 4 months after propensity score matching. Relapse free survival at 3-years was 34% with chemotherapy and 47% with HSCT as post-remission therapy in CR1. Overall survival was also different between treatment groups; 39% vs. 54% with chemotherapy and HSCT. The 3-year cumulative incidence of relapse was 45% vs. 40% with chemotherapy and HSCT while the non-relapse mortality was 21% vs. 13%.